Curis Inc (CRIS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.35-1.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRIS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -83.9% |
| Our one-year growth estimate | diamond | 22.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 106.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRIS — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-07-30
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 24, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”). Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Dis…
Why it matters: The study results will show if the drug is effective. This is key for Curis's future.
Supportive ifThe Phase 2 study shows good results. Patients had better outcomes.
Worry ifThe Phase 2 study shows bad results. There was no improvement and safety issues.
Why it matters: Updates on cash runway will show if Curis can fund operations and trials.
Watch forCuris says it used Series B warrants. This gives them more cash to operate.
Also watch forCuris does not get more funding or faces cash shortages.
Why it matters: Exercising the Series B warrants could give Curis more money to support its work.
Supportive ifA public announcement will say they treated the fifth patient in the TakeAim CLL study. This starts the Series B warrants exercise.
Worry ifNo announcement of dosing the fifth patient by the end of 2026.
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Curis Inc. This could improve investor sentiment.
Supportive ifHealthcare sector revenue growth is speeding up. It could reach 10% or more.
Worry ifHealthcare sector revenue growth is slowing down. It is now below 5%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$363 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,042 loss on $10,000 · 10.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,629 loss on $10,000 · 96.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: They need money to manage cash. Success would help their finances.
Supportive ifThey announced successful PIPE financing. They raised up to $20.2M.
Worry ifFailure to secure PIPE financing or further declines in net income.
Why it matters: Using these warrants could give Curis important funding. This is crucial for ongoing operations.
Supportive ifThey announced the exercise of Series B Warrants. This could bring in up to $20.2 million.
Worry ifNot using Series B Warrants before the dosing announcement shows cash flow issues.
Why it matters: Financing completion is key for the company to keep enough cash.
Supportive ifSeries B warrants from the January 2026 PIPE Financing can be used after treating the 5th CLL patient.
Worry ifFailure to exercise warrants or raise additional funds by mid-2026.
Why it matters: Dosing the first five patients is a key step for Curis's CLL trial. This could lead to important clinical data later in 2026.
Supportive ifCuris announces dosing of the first five patients in the TakeAim CLL study by mid-2026.
Worry ifDosing is delayed beyond mid-2026 without a clear reason.
Why it matters: Using these warrants could bring in cash for ongoing operations.
Supportive ifCuris says it will use Series B Warrants to raise up to $20.2 million.
Worry ifNo exercise of Series B Warrants occurs, limiting cash runway.
Why it matters: New data from the lymphoma study may help with regulatory filings. It could also change how investors feel.
Supportive ifCuris will share new clinical data from the TakeAim Lymphoma study in early 2027.
Worry ifNo new data comes out on time, or the data is not good.